|Year : 2020 | Volume
| Issue : 3 | Page : 307-318
Update on pharmacotherapy in psychodermatological disorders
Shrutakirthi D Shenoi1, Savitha Soman2, Ravindra Munoli2, Smitha Prabhu1
1 Department of Dermatology, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Udupi, Karnataka, India
2 Department of Psychiatry, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Udupi, Karnataka, India
|Date of Submission||27-Jul-2019|
|Date of Decision||28-Sep-2019|
|Date of Acceptance||28-Sep-2019|
|Date of Web Publication||10-May-2020|
Department of Psychiatry, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Udupi - 576 104, Karnataka
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Psychodermatological (PD) conditions encountered in dermatologic practice include primary psychiatric conditions such as delusions of parasitosis or secondary psychiatric conditions such as anxiety and depression due to dermatologic disease. The psychotropics include antipsychotic agents, anti-anxiety agents, antidepressants, and miscellaneous drugs such as anti convulsants. Anti psychotics are further divided into first-generation and second-generation drugs. Currently, second-generation drugs e.g., risperidone are preferred over first-generation drugs e.g., pimozide in delusional infestation owing to the side effect profile of the latter. Anti-anxiety agents include benzodiazepines used in acute anxiety and buspirone in chronic anxiety disorders. They are frequently prescribed along with antidepressants. Although dependence and necessity of tapering is a problem with benzodiazepines, delayed onset of action is a feature of buspirone. The commonly used antidepressants in dermatology include selective serotonin reuptake inhibitors (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline), selective serotonin norepinephrine reuptake inhibitors (venlafaxine, desvenlefaxine, and duloxetine), norepinephrine dopamine reuptake inhibitors (bupropion), tricyclic antidepressants (doxepin, amitriptyline, imipramine, and clomipramine), and tetracyclic antidepressants (mirtazapine). Miscellaneous drugs include anticonvulsants such as gabapentin and pregabalin, naltrexone, and N-acetyl cysteine. The principles of PD treatment are first establish the psychiatric diagnosis, followed by initiating drug treatment. The choice of drugs is dependent on multiple factors such as side-effect profile, drug interactions, and co-morbid conditions. Usually, drugs are started at a low dose and gradually increased. A literature search was done in Pubmed, Google Scholar, and Medline databases, and articles on treatment were analyzed.
Keywords: Anti-anxiety agents, anti convulsants, antidepressants, anti psychotics, N-acetyl cysteinenaltrexone, pharmacotherapy, psychodermatological disorders
|How to cite this article:|
Shenoi SD, Soman S, Munoli R, Prabhu S. Update on pharmacotherapy in psychodermatological disorders. Indian Dermatol Online J 2020;11:307-18
|How to cite this URL:|
Shenoi SD, Soman S, Munoli R, Prabhu S. Update on pharmacotherapy in psychodermatological disorders. Indian Dermatol Online J [serial online] 2020 [cited 2021 Oct 22];11:307-18. Available from: https://www.idoj.in/text.asp?2020/11/3/307/284111
| Introduction|| |
Psychodermatological (PD) conditions are not uncommon in clinical practice. They may present as primary psychiatric disorders such as delusions of parasitosis (DP), dermatitis artefacta etc., or as chronic dermatoses such as atopic eczema or psoriasis, patients of which may have depression or anxiety secondary to their skin disease. In a study from Manipal, 33% of the patients attending a psychodermatology liaison clinic had psychiatric co-morbidity. Since, psychological components contribute to the overall dermatological outcomes, managing them is of importance. It is essential for a clinical dermatologist to have a working knowledge of common psychiatric conditions as well as the use of psychotropic medications. Although DP is infrequently encountered, dysthymia is common in routine practice. Present article addressesrole of psychopharmacotherapy in PD conditions.
| Antipsychotics|| |
Antipsychotics are the drugs of choice in delusional disorders such as DP. They are also useful in body focused repetitive behaviors such as trichotillomania (TTM) and skin picking disorder. Owing to their multi-receptor action, they are sometimes used in pruritus, and hyperhidrosis. They are divided into first-generation antipsychotics (FGAs; neuroleptics, conventional, or typical anti psychotics) and second-generation anti psychotics (SGAs; atypical). The increased incidence of extrapyramidal syndromes (EPS) such as akathisia (feeling of restlessness), Parkinsonism (slow movements, slow speech, tremors, and facial stiffness), tardive dyskinesia (irregular jerky movements), and dystonia (spasms and muscle contractions) with FGAs are the main differences between FGAs and SGAs.
All FGAs act by inhibiting the dopamine D2 receptors in the brain and in addition to EPS, hyperprolactinemia is also seen with their use. Of various agents in FGAs, last decades have witnessed the effective and wide usage of pimozide for DP. It is available as 2 mg and 4 mg tablets and may be started at a dose of 0.5 mg/day and up to 6mg daily at 8–12 hourly intervals. Prophylactic anticholinergics (trihexyphenidyl 2 mg tid, benztropine 1–2 mg qid, or diphenhydramine 25–50 mg every 4 to 6 h) can be given to prevent EPS. In a study of 33 patients with DP who were prescribed pimozide, only 18 took it and on follow-up, five had complete remission, four were less symptomatic, five were unchanged, and four died of unrelated causes. Owing to the high incidence of EPS and cardiac effects such as Q-T interval prolongation with pimozide, it has been superseded by Second Generation A ntipsychotics (SGAs). The drug interactions of pimozide such as serious cardiotoxicity with itraconazole and macrolides, the necessity of frequent monitoring with ECG and serum potassium levels, and the occurrence of neuroleptic malignant syndrome (fever, muscle rigidity, confusion, and dysrhythmias) have precluded its use as a first-line treatment in DP.
Currently, SGAs are the preferred drugs in DP, among which risperidone is considered as the drug of choice. The other drugs in this class are clozapine, olanzapine, quetiapine, aripiprazole, ziprasidone, and lurasidone. SGAs act by binding to D2 receptors as well as to serotonin 5-HT2 receptors. More binding to the latter and the early dissociation from D2 receptors explains the reduced incidence of EPS with SGAs. SGAs have metabolic side effects (weight gain, diabetes, and hyperlipidemia). In a case series of three DP patients started on risperidone 2mg/day increased upto 4–6mg, good improvement was seen within 3 months. In another study on DP, a good response was reported in three patients with olanzapine at a dose of 5mg/day increased to 10 mg. Aripiprazole, considered as a “third-generation antipsychotic,” has also been tried in DP in the dose of 5–10 mg/day. One distinct advantage of aripiprazole over other SGAs is the absence of weight gain.
The principle of treatment is to start with a low dose and gradually titrate upward every 4 weeks depending on the response. During follow-up, all patients on antipsychotics should be questioned about EPS and also get their weight, blood sugars, lipid profile, and blood pressure checked. Elderly patients who are susceptible to side effects such as orthostatic hypertension and neuropsychiatric symptoms should be started with one-fourth to one-half the usual dose and slowly increased. The drug has to be continued till the improvement is maintained for a period of 3–6 months after which it can be tapered or stopped. If there is relapse, the drug can be restarted.
The oral dosing, side effects, and drug interactions of the commonly used anti psychotics are shown in [Table 1]. Adverse effects, monitoring schedule, management strategies of adverse effects of anti psychotics and strategies in selecting anti psychotics have been mentioned in [Table 2], [Table 3], [Table 4], and [Table 5], respectively.
Anti-anxiety agents are chiefly used to mitigate anxiety symptoms seen as part of anxiety and/or other emotional disorders, most often in conjunction with antidepressant medications. Commonly encountered anxiety disorders include panic disorder, obsessive-compulsive disorder, specific phobias, social phobia, generalized anxiety disorder (GAD), and anxiety-related to other specific situations such as performance, health anxiety, etc. In a psychodermatology clinic, they are particularly useful in the management of social anxiety which more often than not accompanies chronic and disfiguring skin conditions.
These are the most commonly prescribed class of anxiolytic agents. They exert their anti-anxiety effect by binding to the benzodiazepine (BDZ) receptors at the gamma aminobutyric acid (GABA)-A ligand-gated chloride channel complex. This enhances the inhibitory effects of GABA and also increases chloride conductance through the GABA-regulated channels. These drugs presumably inhibit neuronal activity in amygdala- centered fear circuits to provide therapeutic benefits in anxiety disorders.
The classification of benzodiazepines and the doses of commonly used drugs are given in [Table 6].
The most commonly reported side effect is that of sedation and day time drowsiness, which is partly dose-dependent. Patients also report weakness, giddiness, and impairment of motor performance such as driving, nausea, slight fall in blood pressure, confusion, and anterograde amnesia. Rarely, respiratory depression can occur, especially when taken with central nervous system (CNS) depressants in overdose. Most of these adverse effects usually wane over time. If they persist, dose may be reduced and the largest dose taken at bedtime to avoid day-time drowsiness. The chief concern with long-term use of BDZ is that it is habit-forming and patients may become dependent on the drug. Long-term use of BDZ may also cause tolerance leading to diminished efficacy at the same dose. Hence, short-term treatment is advocated, during which acute or self-limited episodes of anxiety often resolve.
Features of withdrawal include jitteriness, anxiety, palpitations, clamminess, sweating, nausea, confusion, and heightened sensitivity to sound and light. Seizures are the most worrisome withdrawal symptom, but they are fortunately rare. Patients may experience a rebound of the initial anxiety symptoms, in a more severe form than earlier, however, it is transient, usually lasting about 48–72 h. Hence, it has been advocated that these drugs should always be tapered gradually before discontinuation. One of the rules that have been suggested is to reduce the dose at a maximum rate of approximately 10% every day.
A study on BDZ withdrawal found that withdrawal symptoms on abrupt discontinuation were maximum in patients who had taken the medication for longer than 8 months. As a result of withdrawal, no patient had seizures in this study. Factors associated with a more difficult withdrawal included higher dose, use of a drug with a shorter half-life, longer duration of treatment, and more rapid taper. In the case of long-acting agents such as diazepam, withdrawal symptoms manifest only about 5–7 days after abrupt discontinuation, while they are more quickly evident in case of drugs like lorazepam.
Several medications have been tried in an attempt to alleviate the symptoms of benzodiazepine withdrawal and to make the transition as smooth as possible for the patient. Drugs such as buspirone have been found to be relatively safe, as also melatonin. The antidepressant trazodone relieves anxiety and depression and also promotes sleep while hydroxyzine is an alternative that can be easily procured over-the-counter. However, other medications such as carbamazepine, sodium valproate, lamotrigine, and phenobarbital that have high side-effect profiles and risks of medical complications must be used with caution. The evidence for the use of these drugs as a method of BDZ discontinuation remains poor. Flumazenil, which is used to reverse the effects of benzodiazepines, may precipitate seizures in patients with epilepsy being treated with benzodiazepines. The dosage of anxiolytics would generally need to be reduced in patients with renal, hepatic impairment, and in the pediatric and geriatric population. They are generally not recommended in pregnant and lactating women. A study comparing the efficacy and tolerability of clonazepam with other benzodiazepines in patients with anxiety disorders concluded that all benzodiazepines were equally efficacious in the treatment of anxiety disorders, however, clonazepam exhibited a better adverse effect profile than the other drugs.
It is a 5-HT1A partial agonist, administered orally. The starting dose is 5 mg twice daily, increased upto 20–30 mg/day in divided doses. The major drawback of the drug is the delayed onset of action (2–4 weeks), which precludes its use on an as needed basis. It remains inappropriate for the treatment of acute situational stress because the therapeutic effect may not become evident until after the stressful event has been resolved. Side effects include dizziness, headache, nervousness, sedation, excitement, nausea, and restlessness. It has an advantage over benzodiazepines in that it is not habit-forming, hence does not require tapering before discontinuation. Side effects are time-limited. However, the dose may be reduced if they continue to be troublesome. Buspirone is primarily metabolized by CYP450 3A4, hence, dose needs to be adjusted when used along with inhibitors e.g., fluoxetine or inducers e.g., carbamazepine of the enzyme. A lower dose is also recommended in patients with hepatic and renal impairments and in the elderly. It is safer than benzodiazepines in pregnant and lactating women.
Anti-anxiety drugs are usually prescribed along with antidepressants, at the lowest effective dose. This dose is often continued for a period of 4–6 weeks until the anti-depressant drugs begin to act, following which it is gradually tapered and discontinued. Buspirone may be used for longer periods and does not require taper before discontinuation. The use of concomitant psychological interventions can also help in reducing the duration of treatment with anti-anxiety agents.
Depression can be an underlying, co-existing, or a consequence of the dermatological condition. When features of depression start manifesting and form part of or major component of the skin disease in course of dermatosis, antidepressants are indicated.
Diseases such as alopecia areata and vitiligo have been found to have a bidirectional relationship with depression in large scale cohort studies., A systematic review of 35 studies found that chronic pruritus that is unresponsive to topical treatment and oral antihistamines will benefit from oral antidepressants (fluoxetine, fluvoxamine, paroxetine, sertraline, amitriptyline, nortriptyline, doxepin, and mirtazapine). Indications for antidepressants are outlined in [Table 7].,
Antidepressants commonly used in a dermatologic setting are classified as selective serotonin reuptake inhibitors (SSRIs), selective serotonin-norepinephrine reuptake inhibitors (SNRIs), norepinephrine-dopamine reuptake inhibitors (NDRIs), tricyclic antidepressants (TCAs), and tetracyclic antidepressants (TeCAs). Others such as serotonin modulators and stimulators (SMSs), monoamine oxidase inhibitors (MAOIs), and norepinephrine reuptake inhibitors (NRIs) are rarely used. [Table 8] describes the dose, indications and side effects of antidepressants.,, [Table 9] mentions monitoring recommendations for antidepressants and [Table 10] describes about choosing the right antidepressant.
Selective serotonin reuptake inhibitors
These increase levels of serotonin in the synaptic cleft by inhibiting its reuptake into presynaptic cells. They are preferred as first-line antidepressants due to their better tolerability and favorable side effects profile.
A study to determine if psoriasis was affected by the use of SSRIs showed that the risk of switching from non-systemic to systemic psoriasis treatments was significantly decreased in the SSRI-exposed group. In a retrospective study of 51 patients suffering from primary burning mouth syndrome, SSRIs appeared to be effective and well-tolerated.
Escitalopram is an S-stereoisomer of its predecessor citalopram and has the highest affinity for serotonin receptors among all SSRIs and more cost-effective.
In a double-blind RCT of citalopram (20 mg/day, over 4 weeks) in 45 patients with pathological skin picking, there was a significant improvement with citalopram compared to placebo. In an open-label trial of escitalopram for 18 weeks in 29 patients with pathological skin picking, 44.8% showed full remission and 27.6% showed partial response.
It is useful in neurotic excoriations, pathologic skin picking, and body dysmorphic disorder., In an open-label double-blind study to check the usefulness of fluoxetine in pathological skin picking, of 15 recruited eight responded by 6 weeks. On randomization, four patients on fluoxetine maintained improvement, the other four patients on placebo, returned to baseline symptom level.
Its antidepressant property is enhanced by its affinity (maximum among SSRIs) for the σ1 receptor. It is useful in patients with neurotic excoriations, chronic pruritus, body dysmorphic disorder and trichotillomania (TTM).
In a 12 weeks uncontrolled study of flexible-dose of fluvoxamine (25–50 mg/day - 300 mg/day) over 12 weeks in skin picking, all 14 patients showed significant reduction in behaviors involving the skin (e.g., scratching, picking, gouging, or squeezing), increased control over skin behavior and a significant improvement in the presence of skin sensations, skin appearance, and lesions.
It has been used successfully in patients with TTM and pathologic picking. In a case series of eight adolescents with acne and depression, paroxetine was beneficial in improving both depression and acne. In a double-blind, randomized, placebo-controlled trial with paroxetine in 13 patients (eight-paroxetine and five placebo) with alopecia aerate and psychiatric comorbidity, complete regrowth of hair was seen in two patients on paroxetine, while four showed partial regrowth. Only one in placebo group had an almost complete hair regrowth. It can cause weight gain, memory impairment, paresthesias and reproductive risks, as it may cause sperm DNA fragmentation.
It can be used in the treatment of neurotic excoriations and chronic pruritus. With a response rate of 68% in an open-label trial using flexible-dose of sertraline, it also emerged as a promising agent for reducing skin-picking.
Discontinuation syndrome if SSRIs are abruptly stopped, patients may experience nausea, weakness, dizziness, insomnia, anxiety, irritability and headache. It is seen with paroxetine and fluvoxamine which have short half-lives and less with fluoxetine, which has a longer half-life. Usually, the symptoms tend to resolve within a week and can be prevented by slowly tapering SSRIs over a few weeks.
Serotonin Norepinephrine Reuptake Inhibitors
This group includes drugs that inhibit serotonin and norepinephrine reuptake.
It is considered to be superior to SSRIs and TCAs. It may be particularly useful in patients who have mixed symptoms of depression and anxiety because it has anxiolytic properties.
Duloxetine: Although useful in depression, diabetic neuropathy and somatoform disorders, it has been successfully tried in burning mouth syndrome.
Norepinephrine dopamine reuptake inhibitor
Bupropion is a NDRI and a nicotinic and acetylcholine receptor antagonist. It does not cause sexual dysfunction. It can lower the seizure threshold and can unmask underlying psychosis. Ten patients with psoriasis and ten patients of atopic dermatitis, without depression were studied in a single track open-label treatment with bupropion – sustained release (SR) with 150 mg/day and 300 mg/day doses, given sequentially for 3 weeks with a washout period of 3 weeks. In atopic dermatitis group, six of ten subjects showed a reduction in affected body surface area by the end of 6 weeks of bupropion treatment, with affected area increasing toward the pre-study baseline in all responders following bupropion discontinuation. Eight of ten patients improved after 6 weeks of treatment in psoriasis group. Average reduction in the affected area in the responders at week 6 of treatment was approximately 50% in both groups.
Tricyclic and tetracyclic antidepressants
Both groups of drugs inhibit serotonin and norepinephrine reuptake, in addition they block histamine, muscarinic acetylcholine, and noradrenergic receptors, which account for their antidepressant effects and adverse effects. When imipramine was compared with placebo in a double-blind study of 13 patients for 6 months, five of seven patients receiving imipramine showed significant regrowth of hair, whereas no change was noticed in placebo group.
This is the most relevant and commonly used TCA in dermatology because of its H1 and H2 histamine-blocking activity. It can be considered as first-line “off-label” treatment for neurotic excoriations, generalized pruritus, and chronic urticaria. It is available in the topical cream formulation also for pruritus. In a retrospective, cross-sectional study over a 20-year period (1998-2017) of 36 patients with chronic urticaria who had poor antihistamine responses and received doxepin therapy, 16 (44.4%) patients showed a complete response and it was effective in 27 (75%) patients with a short onset time. In a double-blind cross-over study of 50 patients with chronic idiopathic urticaria, doxepin (10 mg TDS) with diphenhydramine (25 mg TDS), 43% of the patients on doxepin had a complete response (total clearance of pruritus and urticarial lesions), whereas only 5% of patients receiving diphenhydramine had responded; partial or total control of urticaria and itch was found in 74% of patients receiving doxepin and only in 10% of patients on diphenhydramine.
In a case series of 11 patients with scalp dysesthesia, nine benefitted with antidepressants, eight patients experienced improvement/complete resolution with low-dose doxepin or amitriptyline and one patient completely responded to sertraline and hydroxyzine hydrochloride but then experienced a relapse.
It is a tertracyclic antidepressant (TeCA) as well as noradrenergic and specific serotonergic antidepressant that antagonizes adrenergic α2-auto- and α2-heteroreceptors as well as 5-HT2 and 5-HT3 receptors. It is useful for pruritus in patients with malignancy, cholestasis, renal failure, atopic dermatitis, and neurotic excoriations.
In a case series of four cases mirtazapine was found effective for pruritus associated with advanced cancer, cholestasis, and hepatic and renal failure. In an open, uncontrolled pilot study of three non-depressed patients with inflammatory skin diseases and severe nocturnal pruritus, after treatment with mirtazapine, all showed improvement in itching.
Antidepressant medications such as paroxetine (20–50 mg/day), sertraline (25–200 mg/day), fluoxetine (10–60 mg/day), escitalopram (10–20 mg/day), low-dose doxepin (50 mg/day or less), and venlafaxine extended-release (75–150 mg/day) have also been shown to be useful for the treatment of chronic anxiety. Occasionally, use of SSRI's may be associated with a worsening of anxiety symptoms in the initial days of treatment. Ameta-analytic review of studies that compared the use of benzodiazepines and serotonergic antidepressants in patients with generalized anxiety disorder (GAD) concluded that benzodiazepines are a viable treatment option for adults with GAD, particularly in the initial treatment phases. The review, however, did not minimize the role of antidepressant agents as treatment for the same and suggested that the combined use of the two could yield optimum risk-benefit ratio of both the medications.
Cutaneous side effects associated with antidepressants include pruritus, exanthematous rash, urticarial, angioedema, fixed drug reactions, photosensitive reactions, pigmentation, alopecia, psoriasiform reactions, acneiform reaction, seborrheic dermatitis, and hyperhidrosis. Serious reactions such as erythema multi for me, Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), vasculitis, erythroderma, and erythema nodosum have also been reported.
Choosing the right antidepressant: The choice depends on side-effect profile, drug interactions, and comorbid conditions. First-line drugs are generally SSRIs such as escitalopram or sertraline. In those with disturbed sleep, mirtazapine or TCAs are preferred. In overweight patients, bupropion may be tried. It also aids in smoking cessation. SSRIs are safe in pregnancy and lactation. Dose varies from patient to patient. The initial dose is given for atleast 2–3 weeks. The maximum tolerated dose should be given for at–least 6 weeks for assessing efficacy. Treatment should be continued for a minimum of 6 – 9 months.
Selecting antidepressant for pruritus
Selection of antidepressant for pruritus, which is unresponsive to conventional treatment, depends on cause of pruritus, age, and medical comorbidities. In review, paroxetine (20 to 30 mg/d) and mirtazapine (10 to 20 mg/d) have emerged as effective therapeutic options for pruritus due to malignancies. Sertraline (50–150 mg/d) is an effective therapeutic option for pruritus due to chronic kidney disease or cholestasis. Amitriptyline (10 to 25 mg/d) and doxepin (10 to 20 mg/d) have also been useful in uremic pruritus. For unexplained pruritus, not responding to conventional treatment, most evidence is available for paroxetine. Dose titrations have been mentioned in the [Table 8].
PD indications of anti-epileptics include cutaneous neuropathic pain, itch, and complex cutaneous sensory syndromes, where CNS sensitization plays a role, repetitive excoriation behaviors such asprurigo nodularis, lichen simplex chronicus, skin picking, and TTM, psychophysiologic conditions such as urticaria, flushing, and social anxiety.
Carbamazepine has been tried in neuropathic and chronic pain, lamotrigine in pathologic skin picking, and topiramate in neurogenic pruritus, and skin picking. However, all these are not extensively used.
Present review focuses on commonly used drugs i.e., the Gamma aminobutyric acid (GABA) elevators.
Gamma aminobutyric acid elevators or neuroleptics
These are used for relief of neuropathic pain syndromes, peripheral neuropathic and psychogenic itch, brachioradial pruritus, various allodynias, collectively known as cutaneous dysaesthesias. These include gabapentin and pregabalin, which inhibit neuropathic afferent pathway.
Gabapentin is a structural analogue of the neurotransmitter GABA. The starting dose is 300 mg at bedtime, increased by 300 mg every 2 to 3 days upto a maximum of 2400 mg/day. It has a lower potential for abuse. Side effects include somnolence, fatigue, ataxia, dizziness, gastrointestinal upset, dyspnea, peripheral edema, and weight gain.
A study involving 17 women with vulvodynia reported 82% response rate to gabapentin a case series of 4 patients with glossodynia responded well to gabapentin and another study on recalcitrant prurigo nodularis also reports good efficacy.
Gabapentin has an off-label use for anxiety disorders. The onset of action is less rapid than benzodiazepines but faster than buspirone. The potential for abuse is lower, and it confers an added advantage of anti-pruritic effect.
Pregabalin is used at a dose of 150 mg per day, to a maximum of 600 mg per day. For neuropathic pruritus, starting dose is 75 mg bd, then slowly increased upto 300 mg per day. Side effects include dryness of mucosae, constipation, nausea, vomiting, flatulence, drowsiness, memory impairment, and rarely, serious cutaneous adverse reactions like SJS. Peripheral edema is encountered in 4–16% cases and weight gain in 4–12%.
Withdrawal of neuroleptics should be gradual, over a period of time, and should be used with caution in congestive cardiac failure (CCF) and renal impairment. Dosage adjustment is not required in hepatic disease and depends on the creatinine clearance rate in renal disease.
This is an opioid antagonist chiefly used in the treatment of alcohol use disorder and opioid abuse but has an off-label indication for treating cholestatic pruritus and psychogenic pruritus as well as intractable pruritus contributing to psychological stress in inflammatory disorder. A systematic review evaluating 22 RCTs, case series, and reports for the utility of naltrexone in dermatology found it to be effective in intractable pruritus associated with inflammatory diseases. Low dose naltrexone (1.5–4.5 mg/day) was more effective as an anti-inflammatory agent in dermatology than high dose naltrexone (12.5–50 mg/day). A meta-analysis of RCTs on naltrexone in the treatment of broadly defined behavioral addictions, which included TTM and skin picking showed a beneficial effect. Dose adjustment is warranted in moderate to severe renal failure, and it is contraindicated in severe hepatic failure. Adverse effects include syncope, dizziness, headache, insomnia, nausea, vomiting, abdominal pain, anorexia, arthralgia, myalgia, pharyngitis, and increased levels of AST, ALT, CPK, and GGT.
This thiol amino acid, a donor of cysteine, restores extracellular glutamate within the nucleus accumbens, the area of the brain associated with reward and motivation. It also alters dopamine level in neurons and has additional anti-inflammatory, potent antioxidant, vasodilator, and antiproliferative effects on fibroblasts and keratinocytes.
Indications include TTM, trichoteiromania, onychotillomania, onychophagia, skin picking, and neurotic excoriations. Usual dose is 1200 mg per day, given as 600 mg bd, increased upto a maximum of 3000 mg per day. Cochrane's systemic review demonstrates good evidence for its usefulness in TTM. There are studies substantiating as well as refuting its effectiveness in TTM.
At1, 200–2,400 mg per day, N-acetyl cysteine (NAC) significantly improved TTM showing a 56% improvement in TTM scale, as compared with placebo. An RCT in skin picking (excoriation disorder) found it to be effective with very good improvement in 47% cases. In onychophagia, an RCT showed statistically significant short-term improvement on 800 mg NAC per day, though many relapsed. Side effects include disagreeable taste, nausea, vomiting, abdominal pain, constipation, urticaria, skin rash, fever, and headache. It is contra-indicated in patients on nitroglycerine as it can cause vasodilatory hypotension and reverse the tolerance to nitroglycerates.
This is a milk protein hydrosylate, which contains a bioactive decapeptide, α-casozepine. It is a non-sedative, non-addictive anxiolytic which is claimed to be helpful in disease-associated anxiety by potentiating the effect of GABA by binding to GABA-A receptors causing an influx of chloride ions which hyperpolarizes the neurons and decreases the transmission of stress signals. In spite claims, there are no studies regarding its efficacy.
Children, adolescents, geriatric age group patients and patients with medical comorbidities constitute this group. General dictum for the usage of psychotropics in the geriatric population is “start low, go slow”. For children and adolescents, lowest possible doses are suggested. The selection of psychotropic will depend on a person's medical comorbidity.
| Conclusions|| |
Patients with the suspected psychodermatologic disease should be assessed with a thorough psychiatric history. The appropriate psychotropics may be started according to the psychiatric diagnosis. It is better to be familiar with one or two drugs from each class. Usual doses required for treatment in dermatological conditions are much lesser than what are used in psychiatry. Adverse effects encountered with psychotropics are usually at higher doses, which are used for major psychiatric disorders, and at doses used in dermatology, chances of encountering adverse effects are minimal. However, the selection of a psychotropic depends on condition and comorbidities of patient and personalized therapy is the need of 3 h rather than one drug for one condition for all. Starting with a low dose and gradual escalation, being watchful for side effects and tapering before discontinuation is the key to effective management.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Goyal N, Shenoi S, Prabhu SS, Shreejayan K, Munoli R, Rai S. Psycho dermatology liaison clinic in India: A working model. Trop Doct 2018;48:7-11.
Shenoi SD, Prabhu S, Nirmal B, Petrolwala S. Our experience in a psychodermatology liaison clinic at Manipal, India. Ind J Dermatol 2013;58:53-5.
Freudenmann RW, Lepping P. Delusional infestation. Clin Microbiol Rev 2009;22:690-732.
Van Ameringen M, Mancini C, Patterson B, Bennett M, Oakman J. A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. J Clin Psychiatry 2010;71:1336-43.
Gupta MA, Gupta AK. Olanzapine is effective in the management of some self-induced dermatoses: Three case reports. Cutis 2000;66:143-6.
Shanon J. A dermatologic and psychiatric study of perphenazine (trilafon) in dermatology. AMA Arch Dermatol 1958;77:119-20.
Smith MA, Curwen MP. Controlled trials of two oral antipruritic drugs, trimeprazine and methdilazine. Br J Dermatol 1961;73:351-8.
Dickmann LM, Dickmann JR. Quetiapine in the treatment of hyperhidrosis axillaris. Br J Dermatol 2010;163:1126-7.
Zomer SF, De Wit RF, Van Bronswijk JE, Nabarro G, Van Vloten WA. Delusions of parasitosis. A psychiatric disorder to be treated by dermatologists? An analysis of 33 patients. Br J Dermatol 1998;138:1030-2.
Campbell EH, Elston DM, Hawthorne JD, Bekert DR. Diagnosis and management of delusions of parasitosis. J Am Acad Dermatol 2019;80:1428-34.
Sawant NS, Vispute CD. Delusions of parasitosis with folie a deux: A case series. Ind Psychiatry J 2015;24:97-8.
] [Full text]
Meehan WJ, Badreshia S, Mackley CL. Successful treatment of delusions of parasitosis with olanzapine. Arch Dermatol 2006;142:352-5.
Ladizinski B, Busse KL, Bhutani T, Koo JY. Aripiprazole as a viable alternative for treating delusions of parasitosis. J Drugs Dermatol 2010;9:1531-2.
Duvar H, Sengul C, Herken H. Aripiprazole in delusional disorder. Eur J Gen Med 2010;7:433-5.
Gupta MA, Vujcic B, Pur DR, Gupta AK. Use of antipsychotic drugs in dermatology. Clin Dermatol 2018;36:765-73.
Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. World Psychiatry 2018;17:341-56.
Schatzberg AF, Cole JO, DeBattista C. Manual of Clinical Psychopharmacology. 4th
ed. Washington: American Psychiatric Press; 2003.
Ghosh S, Behere R, Sharma PS, Soman S. Relevant issues in pharmacotherapy of psychocutaneous disorders. Indian J Dermatol 2013;58:61-4.
] [Full text]
Park KK, Koo J. Use of psychotropic drugs in dermatology: Unique perspectives of a dermatologist and psychiatrist. Clin Dermatol 2013;31:92-100.
Rickels K, Case WG, Downing RW, Winokur A. Long term diazepam therapy and clinical outcome. JAMA 1983;250:767-71.
Rickels K, De Martinis N, Rynn M, Mandos L. Pharmacologic strategies for discontinuing benzodiazepine treatment. J Clin Psychopharmacol 1999;19(6 Suppl 2):12-6.
Fluyau D, Revadigar N, Manobianco BE. Challenges of the pharmacological management of benzodiazepine withdrawal, dependence, and discontinuation. Ther Adv Psychopharmacol 2018;8:147-68.
Wang SM, Kim JB, Sakong JK, Suh H, Oh KS, Woo JM, et al.
The efficacy and safety of clonazepam in patients with anxiety disorder taking newer antidepressants: A multicenter naturalistic study. Clin Psychopharmacol Neurosci 2016;14:177-83.
Lee CS, Accordino R, Howard J, Koos J. Psychopharmacology in Dermatology. DermatolTher 2008;21:69-82.
Vallerand IA, Lewinson RT, Parsons LM, Hardin J, Haber RM, Lowerison MW, et al.
Assessment of a bidirectional association between major depressive disorder and alopecia areata. JAMA Dermatol 2019;155:475-9.
Vallerand IA, Lewinson RT, Parsons LM, Hardin J, Haber RM, Lowerison MW, et al.
Vitiligo and major depressive disorder: A bidirectional population-based cohort study. J Am Acad Dermatol 2019;80:1371-9.
Kouwenhoven TA, van de Kerkhof PC, Kamsteeg M. Use of oral antidepressants in patients with chronic pruritus: A systematic review. J Am Acad Dermatol 2017;77:1068-73.
Munoli R. Primary Psychiatric Disorders – Cutaneous Manifestations. In: Latheef AE, Prabhu SS, Shenoi SD, editors. Handbook of Psychodermatology. 1st
ed. New Delhi: Jaypee Brothers Medical Publishers PLtd; 2016. p. 30-49.
Kongasseri S. Secondary psychiatric disorders in dermatology patients. In: Latheef AE, Prabhu SS, Shenoi SD, editors. Handbook of Psychodermatology. 1st
ed. New Delhi: Jaypee Brothers Medical Publishers PLtd; 2016. p. 50-62.
Wolverton SE, editor. Comprehensive Dermatologic Drug Therapy. 3rd
ed. Philadelphia: WB Saunders 2001. p. 402-25.
Lee CS, Koo JY. Use of Psychotropics in dermatology. In: Koo JY, Lee CS, editors. Pychocutaneous Medicine. 1st
ed. New York: Marcel Dekker Pubihsers; 2003. p. 427-52.
Ferguson JM. SSRI antidepressant medications: Adverse effects and tolerability. Prim Care Companion J Clin Psychiatry 2001;3:22-7.
Dodd S, Mitchell PB, Bauer M, Yatham L, Young AH, Kennedy SH, et al.
Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement. World J Biol Psychiatry 2018;19:330-48.
Thorslund K, Svensson T, Nordlind K, Ekbom A, Fored CM. Use of serotonin reuptake inhibitors in patients with psoriasis is associated with a decreased need for systemic psoriasis treatment: A population-based cohort study. J Intern Med 2013;274:281-7.
Fleuret C, Le Toux G, Morvan J, Ferreira F, Chastaing M, Guillet G, et al.
Use of selective serotonin reuptake inhibitors in the treatment of burning mouth syndrome. Dermatology 2014;228:172-6.
Garnock-Jones KP, McCormack PL. Escitalopram: A review of its use in the management of major depressive disorder in adults. CNS Drugs 2010;24:769-76.
Arbabi M, Farnia V, Balighi K, Mohammadi MR, Nejati-Safa AA, Yazdchi K, et al.
Efficacy of citalopram in treatment of pathological skin picking: A randomized double blind placebo controlled trial. Acta Med Iran 2008;46:367-72.
Keuthen NJ, Jameson M, Loh R, Deckersbach T, Wilhelm S, Dougherty DD. Open-label escitalopram treatment for pathological skin picking. Int Clin Psychopharmacol 2007;22:268-74.
Simione D, Stein D, Gross S, Islam N, Schmeidler J, Hollander E. A double-blind trial of fluoxetine in pathologic skin picking. J Clin Psychiatry 1997;58:341-7.
Cotterill JA. Body dysmorphic disorder. Dermatol Clin 1996;14:457-63.
Masand PS, Gupta S. Selective serotonin-reuptake inhibitors: An update. Harv Rev Psychiatry 1999;7:69-84.
Arnold LM, Mutasim DF, Dwight MM, Lamerson CL, Morris EM, McElroy SL. An open clinical trial of fluvoxamine treatment of psychogenic excoriation. J Clin Psychopharmacol 1999;19:15-8.
Ravindran A, Lapierre Y, Anisman H. Obsessive-compulsive spectrum disorders: Effective treatment with paroxetine. Can J Psychiatry 1999;44:805-7.
Moussavian H. Improvement of acne in depressed patients treated with paroxetine. J Am Acad Child Adolesc Psychiatry 2001;40:505-6.
Cipriani R, Perini GI, Rampinelli S. Paroxetine in alopecia areata. Int J Dermatol 2001;40:600-1.
Tanrikut C, Feldman AS, Altemus M, Paduch DA, Schlegel PN. Adverse effect of paroxetine on sperm. Fertil Steril 2010;94:1021-6.
Kalivas J, Kalivas L, Gilman D, Hayden CT. Sertraline in the treatment of neurotic excoriations and related disorders. Arch Dermatol 1996;132:589-90.
Zajecka J, Tracy KA, Mitchell S. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: A literature review. J Clin Psychiatry 1997;58:291-7.
O'Donnell JM, Shelton RC. Drug therapy of depression and anxiety disorders. In: Brunton IL, editor. Goodman and Goodman's the Pharmacological Basis of Therapeutics. 12th
ed. New York: McGraw-Hill Medical Publishing Division; 2006. p. 398-413.
Mignogna MD, Adamo D, Schiavone V, Ravel MG, Fortuna G. Burning mouth syndrome responsive to duloxetine: A case report. Pain Med 2011;12:466-9.
Munoli RN, Kongasseri S, Praharaj SK, Sharma PS. Bupropion precipitating acute psychosis: A case report. Am J Ther 2014;21:e45-7.
Modell JG, Boyce S, Taylor E, Katholi C. Treatment of atopic dermatitis and psoriasis vulgaris with bupropion-SR: A pilot study. Psychosom Med 2002;64:835-40.
Perini G, Zara M, Cipriani R, Carraro C, Preti A, Gava F, et al.
Imipramine in alopecia areata. A double-blind, placebo-controlled study. Psychother Psychosom 1994;61:195-8.
Tennyson H, Levine N. Neurotropic and psychotropic drugs in dermatology. Dermatol Clin 2001;19:179-97.
Özkaya E, Kobaner GB, Yılmaz Z, Kutlay A. Doxepin in difficult-to-treat chronicurticaria: A retrospective, cross-sectional study from Turkey. Dermatol Ther 2019;32:e12993.
Greene SL, Reed CE, Schroeter AL. Double-blind crossover study comparing doxepin with diphenhydramine for the treatment of chronic urticaria. J Am Acad Dermatol 1985;12:669-75.
Hoss D, Segal S. Scalp dysesthesia. Arch Dermatol 1998;134:327-30.
Anttila SA, Leinonen EV. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev 2001;7:249-64.
Davis MP, FrandsenJL, Walsh D, Andresen S, Taylor S. Mirtazapine for pruritus. J Pain Symptom Manage 2003;25:288-91.
Hundley JL, Yosipovitch G. Mirtazapine for reducing nocturnal itch in patients with chronic pruritus: A pilot study. J Am Acad Dermatol 2004;50:889-91.
Yadav S, Narang T, Kumaran MS. Psychodermatology: A comprehensive review. Indian J Dermatol Venereol Leprol 2013;79:176-92. [Full text]
Gomez AF, Barthel AL, Hoffman SG. Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: A meta-analytic review. Expert Opin Pharmacother 2018;19:883-9.
Bliss SA, Warnock JK. Psychiatric medications: Adverse cutaneous drug reactions. Clin Dermatol 2013;31:101-9.
Wolfgang HW, Gieler U, Kusnir D, Tausk FA. Psychopharmacological therapy in dermatology. In: Clinical Management in Psychodermatology. 1st
ed. New York: Springer Publications; 2009. p. 239-58.
Gupta MA, Pur DR, Vujcic B, Gupta AK. Use of antiepileptic mood stabilizers in dermatology. Clin Dermatol 2018;36:756-64.
Grant JE, Odlaug BL, Chamberlain SR, Kim SW. A double-blind, placebo-controlled trial of lamotrigine for pathological skin picking: Treatment efficacy and neurocognitive predictors of response.J Clin Psychopharmacol 2010;30:396-403.
Janowsky DS, Kraus JE, Barnhill J, Elamir B, Davis JM. Effects of topiramate on aggressive, self-injurious, and disruptive/destructive behaviors in the intellectually disabled: An open-label retrospective study.J Clin Psychopharmacol 2003;23:500-4.
Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al.
Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis. Lancet Neurol 2015;14:162-73.
Ben-David B, Friedman M. Gabapentin therapy for vulvodynia. Anesth Analg 1999;89:1459-60.
Meiss F, Fiedler E, Taube KM, Marsch WC, Fischer M. Gabapentin in the treatment of glossodynia. Dermatol Psychosom 2004;5:17-21.
Dereli T, Karaca N, Inanir I, Oztürk G. Gabapentin for the treatment of recalcitrant chronic prurigo nodularis. Eur J Dermatol 2008;18:85-6.
Lee B, Elston DM. The uses of naltrexone in dermatological conditions. J Am Acad Dermatol 2019;80:1746-52.
Ekelem C, Juhasz M, Khera P, Mesinkovska NA. Utility of naltrexone treatment for chronic inflammatory dermatologic conditions: A systematic review. JAMA Dermatol 2019;155:229-36.
Mouaffak F, Leite C, Hamzaoui S, Benyamina A, Laqueille X, Kebir O. Treatment of broadly defined behavioral addictions: A review and meta-analysis of randomized controlled trials. Eur Addict Res 2017;23:204-10.
Adil M, Amin SS, Mohtashim M. N-acetylcysteine in dermatology. Indian J Dermatol Venereol Leprol 2018;84:652-9.
] [Full text]
Grant JE, Chamberlain SR, Redden SA, Leppink EW, Odlaug BL, Kim SW. N-acetylcysteine in the treatment of excoriation disorder: A randomized clinical trial. JAMA Psychiatry 2016;73:490-6.
Grant JE, Odlaug BL, Kim SW. Nacetylcysteine, a glutamate modulator, in the treatment of trichotillomania: A double blind, placebocontrolled study. Arch Gen Psychiatry 2009;66:756-63.
Bloch MH, Panza KE, Grant JE, Pittenger C, Leckman JF. Nacetylcysteine in the treatment of pediatric trichotillomania: A randomized, doubleblind, placebocontrolled addon trial. J Am Acad Child Adolesc Psychiatry 2013;52:231-40.
Ghanizadeh A, Derakhshan N, Berk M. N-acetylcysteine versus placebo for treating nail biting, a double blind randomized placebo controlled clinical trial. Antiinflamm Antiallergy Agents Med Chem 2013;12:223-8.
Nixiyax.org [homepage on the Internet]. Curatio Healthcare (I) Pvt. Ltd. Available from: http://www.niiyax.com/
. [updated 2019; Last cited on 2019 May 27].
[Table 1], [Table 2], [Table 3], [Table 4], [Table 5], [Table 6], [Table 7], [Table 8], [Table 9], [Table 10]